A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Clinical trial NCT05228470 · COMPLETED

Trial details

NCT number: NCT05228470
Sponsor: Pfizer
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Elranatamab Myeloma Multiple Myeloma Relapsed Multiple Myeloma Refractory Multiple Myeloma PF-06863135 BCMA Bispecific Bispecific Antibody BCMA-CD3 Bispecific MagnetisMM-8

Start date: 2021-12-21
Primary completion: 2023-08-06
Enrollment: 39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.